A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
Clinical trial NCT03670888 · TERMINATED
Trial details
- NCT number
- NCT03670888
- Sponsor
- JHL Biotech, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-16
- Primary completion
- 2019-03-19
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.